Figure 6
Autophagy inhibition chloroquine enhances the anti-tumor effect of PLX4032 in HT29 xenograft models.
(A) A typical case in each group. (B) Tumors from nude mice in each group. (C–E) Tumor volume, tumor weight and body weight in each group. (F) Tumor lysate was subjected to Western blot for LC3 and βActin. (G) Tumor lysate was subjected to immunoblotting for phospho-MEK1/2 (Ser221), phospho-Erk1/2, phospho-p90RSK (Ser363), phospho-AMPKα (Thr172), LC3 and βActin. BRAF mutant CRC xenografts derived from HT29 cells were treated with Control (vehicle plus PBS), PLX4032 alone (50 mg/kg, twice daily), CQ alone (60 mg/kg, daily), or combination therapy (PLX4032 plus CQ) for 13 day (Day0 – Day12). Average percent change in tumor volume relative to initial tumor volume is shown. Error bars represent SD. Asterisks represent p < 0.05 for combined PLX4032 plus CQ vs. all other treatment groups.
